Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination Dry Powder Inhalers (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Validation of questionnaire and assessment of patient satisfaction for budesonide/formoterol fix combination DPI in COPD
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provision of subject informed consent and to be an outpatient
Clinical diagnosis of COPD according to ICD-10 classification, females and males, aged ≥ 40 years
To be prescribed a fixed dose combination of inhaled budesonide/formoterol fix combination at least 3 months before the study start
You may not be if
Pregnancy for women
Use of inhaled medication via a metered dose inhaler (pMDI)
Currently participating in randomized clinical trials and being included in this study once
Clareo Health | Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination Dry Powder Inhalers (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
